Editas Medicine grants CMO 950K stock options
Editas Medicine granted its Chief Medical Officer stock options for 950,000 shares at a $3.03 exercise price, vesting over four years.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Editas Medicine, Inc. (EDIT) reported that EVP and Chief Medical Officer Daniel Scott Ory received a grant of stock options covering 950,000 shares of common stock on September 8, 2026. The options have an exercise price of $3.03 per share and are scheduled to vest over four years, with 25% vesting on October 15, 2027 and the remaining 75% vesting in equal monthly installments through October 15, 2030. Following this grant, he holds 950,000 stock options directly, which expire on September 7, 2036.
Insider Trade Summary
Grant/Award: 950,000 shares
Grant/Award
1 txn
Insider
Ory Daniel Scott
Role
EVP, Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1 | 950,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 950,000 contracts (Direct)
Footnotes (1)
- F1. This option was granted on September 8, 2026 and is scheduled to vest over four years, with 25% of the shares to vest on October 15, 2027 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through October 15, 2030.
Key Figures
Stock options granted: 950,000 options
Underlying common shares: 950,000 shares
Exercise price: $3.03 per share
+4 more
7 metrics
Stock options granted
950,000 options
Grant to EVP, Chief Medical Officer on September 8, 2026
Underlying common shares
950,000 shares
Each option represents the right to buy one share of common stock
Exercise price
$3.03 per share
Exercise price for the granted stock options
Initial vesting date
October 15, 2027
Date when 25% of the option shares are scheduled to vest
Final vesting date
October 15, 2030
End of the vesting period for the remaining option shares
Expiration date
September 7, 2036
Expiration of the granted stock options if not exercised earlier
Options held after transaction
950,000 options
Total stock options reported as held directly after the grant
Key Terms
Stock Option, vest, exercise price, expiration date
4 terms
Stock Option financial
"This option was granted on September 8, 2026 and is scheduled to vest over four years"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vest financial
"is scheduled to vest over four years, with 25% of the shares to vest on October 15, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"The options have an exercise price of $3.03 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"which expire on September 7, 2036"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did EDIT report for Daniel Scott Ory?
Editas Medicine reported that Daniel Scott Ory received a grant of stock options for 950,000 shares of common stock on September 8, 2026, as part of his equity compensation.
What is the exercise price of the new stock options granted by EDIT?
The stock options granted to Daniel Scott Ory have an exercise price of $3.03 per share for the underlying Editas Medicine common stock.
How do the EDIT stock options granted to the Chief Medical Officer vest?
The options are scheduled to vest over four years: 25% of the shares vest on October 15, 2027, and the remaining 75% vest in equal monthly installments through October 15, 2030.
When do the newly granted EDIT stock options expire?
The stock options granted to Daniel Scott Ory are scheduled to expire on September 7, 2036, if not exercised earlier and subject to the terms of the grant.
How many Editas Medicine stock options does Daniel Scott Ory hold after this grant?
Following this grant, Daniel Scott Ory is reported to hold 950,000 stock options for Editas Medicine common stock as a direct holding.
Were the EDIT stock option grants made under a Rule 10b5-1 trading plan?
The filing indicates that the Rule 10b5-1 trading plan affirmation box was not checked, so these option grants are not reported as made under a Rule 10b5-1 plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
